WCN26-4565 Effectiveness and safety of zuberitamab in membranous nephropathy patients : a multicenter retrospective study

Read full text Summarise with VIRAT
Authors: Dan Yu, Junjun Zhang, Zhanzheng Zhao, Huixia Cao, Lijie He, Mengli Tong, Xuanyi Du, Yun Liu, Gaosi Xu, Dongsheng Ren, Tingjun Zhao, Bo Zhang
+1 more Junxia Wang
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Membranous nephropathy (MN) is the leading cause of nephrotic syndrome in adults. B-cell hyperactivity plays a crucial role in the pathogenesis of membranous nephropathy. Anti-CD20 monoclonal antibodies are the first-line treatment option for MN as recommended by the KDIGO guidelines. Zuberitamab, an innovative anti-CD20 monoclonal antibody, has shown intense antibody-dependent cellular cytotoxicity. To date, studies assessing MN patients treated with zuberitamab are scarce. This study aims to evaluate the real-world effectiveness and safety of zuberitamab in MN patients.

Fields of Study & Subjects

Renal Diseases and Glomerulopathies Systemic Lupus Erythematosus Research Vasculitis and related conditions

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105606–105606
Publication date
25 March 2026
Language
EN